PureTech Health plc PRTCY
16.01 USD +0.70 (+4.57%)
Nov 3, 2026, 9:52 AM EST
16.01 Day range 16.01
13.93 52-week range 19.92
- YTD
- -3.79%
- 1 year
- -9.80%
- Market cap
- 392.53M
- YTD return
- -3.79%
- 1-year return
- -9.80%
- Volume
- 1
- Avg volume
- 2.42K
- Open
- 16.01
- Previous close
- 15.31
- Day's range
- 16.01 – 16.01
- 52-week range
- 13.93 – 19.92
1M +1.96 (+13.95%)
Financials — quick view
PRTCY Revenue — annual 4.66M
PRTCY Net income — annual -109.74M
PRTCY EPS — annual -4.60
News
PureTech Health Wins 2026 Prix Galien USA Award in Incubators, Accelerators and Equity Category 
PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 
PureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026 
PureTech Health plc (PRTCY) Q2 2026 Earnings Call Transcript 
PureTech Health H1 Earnings Call Highlights 
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) 
PureTech Founded Entity Celea Therapeutics to Deliver Two Presentations at the Upcoming European Respiratory Society (ERS) Congress
Your note
Sign in to keep a note on PRTCY — it syncs with the Stock Master app.